Regional Variation in Human Supraspinatus Tendon Proteoglycans: Decorin, Biglycan, and Aggrecan

Paul E. Matuszewski, Yi-Ling Chen, Spencer E. Szczesny, Spencer P. Lake, Dawn M. Elliott, Louis J. Soslowsky, George R. Dodge

Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA

Abstract

While tendons typically undergo primary tensile loading, the human supraspinatus tendon (SST) experiences substantial amounts of tension, compression, and shear in vivo. As a result, the functional roles of the extracellular matrix components, in particular the proteoglycans (PGs), are likely complex and important. The goal of this study was to determine the PG content in specific regions of the SST that exhibit differing mechanical function. The concentration of aggrecan, biglycan, and decorin was determined in six regions of the human SST using immunochemical techniques. We hypothesized that aggrecan concentrations would be highest in areas where the tendon likely experiences compression; biglycan levels would be highest in regions likely subjected to injury and/or active remodeling such as the anterior regions; decorin concentrations would be highest in regions of greatest tensile stiffness. Our results generally supported these hypotheses and demonstrated that aggrecan and biglycan share regional variability, with increased concentration in the anterior and posterior regions and smaller concentration in the medial regions. Decorin, however, was in high concentration throughout all regions. The data presented in this study represent the first regional measurements of PG in the SST. Together with our previous regional measurements of mechanical properties, these data can be used to evaluate SST structure–function relationships. With knowledge of the differences in specific PG content, their spatial variations in the SST, and their relationships to tendon mechanics, we can begin to associate defects in PG content with specific pathology, which may provide guidance for new therapeutic interventions.

Keywords: ELISA, extracellular matrix, shoulder, biomechanics

INTRODUCTION

Tendon is a connective tissue that undergoes primary tensile loading. While the most abundant protein is type-I collagen [1], proteoglycans (PGs), comprising 1–5% of tendon dry weight, are extracellular matrix proteins that play an important role in collagen fibril formation and in resisting compressive loads [1–4]. There are a number of PGs in tendon, each with a distinct core protein and numerous attached glycosaminoglycan (GAG) chains. The most common PG found in tendon is decorin, a small leucine-rich PG [1–3]. Other PGs expressed in tendon include biglycan, aggrecan, fibromodulin, versican, syndecan, and perlecan [5,6]. It has been suggested that these PGs may play a role in functions such as fibrillogenesis, fiber lubrication, and aggregation [7,8]. The mechanical role of PGs in tendon remains controversial, with some studies demonstrating an important role [9] and others reporting no role [10]. This study aims to characterize the PGs decorin, biglycan, and aggrecan in the human supraspinatus tendon (SST). Of the four muscle–tendon complexes comprising the shoulder rotator cuff, the SST is the most commonly injured [11–13]. While tendons typically undergo primary tensile loading, the SST likely experiences multi-axial and heterogeneous loads due to the wide range of motion of the shoulder [14], contact with the coracoacromial arch [15,16], its position over the humeral head [17], and interaction with other rotator cuff tendons [18]. In addition, the insertion site supports multi-axial loading in vivo [11–13,19,20]. These functional requirements are matched by regional variations in longitudinal and transverse tensile properties as well as collagen fiber alignment [21,22]. It is unknown whether PGs exhibit a similar regional variation.

Address correspondence to George R. Dodge, PhD, Department of Orthopaedic Surgery, McKay Orthopaedic Research Laboratory, University of Pennsylvania, 424 Stemmler Hall, 36th Street and Hamilton Walk, 19104-6081 Philadelphia, PA, USA.
E-mail: gdodge@upenn.edu

Received 12 April 2011; Revised 2 December 2011; Accepted 31 December 2011
Decorin, a small leucine-rich PG with a core protein of approximately 40 kDa in size, has one GAG chain consisting of chondroitin sulfate (CS) and is the most abundant PG found in tendons. It has been shown to play a role in collagen fibrillogenesis and has been postulated to help support tensile loading by providing cross-links between collagen fibers [8]. Biglycan, another small leucine-rich PG, shows significant sequence homology to decorin; however, it contains two CS or dermatan sulfate GAG chains. Its specific role is largely unknown, but it is present in the short-term repair response to injury [23]. In addition, both biglycan and aggrecan syntheses increase two- and fourfold, respectively, under compressive load during in vitro culture testing [24].

Aggrecan, with a core protein size of approximately 250 kDa, forms large aggregates with hyaluronan, which itself can be as large as several million kilodaltons. Primarily known as a structural component of articular cartilage, aggrecan can contain as many as 100 GAGs which are primarily CS and keratin sulfate chains. These highly negatively charged polysaccharides provide a hygroscopic environment which aids in water recruitment and resistance of compressive loads [25].

Despite the functional association with PGs in cartilage, little is known regarding the relative composition of specific PGs or their functional role in tendon. In regard to noncollagenous composition, most of the tendon literature has focused on the overall GAG content [26]. However, given the inter- and intra-variability of GAG content amongst specific PGs, GAG composition is only a surrogate marker for PG composition and not representative of individual PG content nor of specific PG core proteins (e.g., decorin, biglycan, aggrecan). The characterization of SST PG content by measuring the specific PG core proteins has not been previously reported. Therefore, the objective of this study was to first develop methodology suitable to assess PG in tendon and, second, to determine the PG content in specific regions of the SST that exhibit varying mechanical properties [21,22]. We hypothesize that (1) aggrecan will be present at the highest levels where tendon is likely to undergo compression, such as the bursal regions; (2) biglycan concentrations will also be highest in the bursal regions as well as in regions likely subjected to injury or active remodeling, such as in anterior regions [24]; and (3) decorin will be ubiquitous throughout the SST but most abundant in areas subjected largely to tension (rather than compression) such as in the medial region away from the insertion site.

**METHODS**

**Sample Preparation**
A total of 121 individual samples were harvested from 27 cadaver shoulders. Samples were taken from the same cadaveric shoulders evaluated in previous mechanical studies [21,22]; specifically, biochemical tissue samples were acquired from locations immediately adjacent to each mechanical test strip. The number of specimens for each region that were evaluated for each PG is noted in Table 1. The average age of the 27 cadavers that were studied was 56 ± 14 years. Donors had no reported history of injury to the shoulder and SSTs, and partial or full-thickness tears were excluded from study. All soft tissue was removed from around the SST, which was separated from the joint capsule and any remaining muscle fibers. The SST was sharply excised from its humeral insertion. Hydration of the SST was maintained using phosphate-buffered saline (PBS) throughout dissection and sample preparation. Rectangular full-thickness samples (~3 × 4 mm) were cut from each SST’s anterior (A), medial (M), and posterior (P) regions. Samples were rapidly thawed in cold water and the dissection occurred over 1–1.5 hrs using PBS (no protease inhibitors) rinses to maintain tissue hydration. These samples were then bisected through their thickness with a scalpel to produce bursal (B) and joint (J) samples yielding six location-specific regions [Figure 1: anterior bursal (AB), anterior joint (AJ), posterior bursal (PB), posterior joint (PJ), medial bursal (MB), and medial joint (MJ)] (n = 16–22 samples per region; Table 1). The samples were then homogenized using a Spex Freezer Mill (Metuchen, NJ, USA) with the following settings (5 min pre-cool, three impaction cycles at 10 Hz for 2 min with 1 min pause intervals). A small aliquot was saved for lyophilization and dry weight determination.

**Proteoglycan Extraction**
Each tendon was extracted using 4M guanidine-HCl/0.5 M sodium acetate and 1× protease inhibitor (Complete, Roche, Indianapolis, IN, USA) in glass scintillation vials at 4°C for 48–72 hrs under constant agitation using a magnetic stir-plate (650 rpm). After 24 hrs, samples that were not completely homogeneously suspended underwent manual agitation using micropipette tip. Adequate extraction and suspension was confirmed qualitatively by white color and viscous appearance. Samples were centrifuged for 15 min at 15,000 × g at 4°C and the supernatant was retrieved and immediately transferred into Slide-A-Lyzer Dialysis

---

**Table 1. Number of specimens assayed in each region for each PG**

<table>
<thead>
<tr>
<th></th>
<th>AB</th>
<th>AJ</th>
<th>MB</th>
<th>MJ</th>
<th>PB</th>
<th>PJ</th>
<th>Total/PG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decorin</td>
<td>21</td>
<td>20</td>
<td>21</td>
<td>21</td>
<td>20</td>
<td>18</td>
<td>121</td>
</tr>
<tr>
<td>Aggrecan</td>
<td>22</td>
<td>21</td>
<td>21</td>
<td>21</td>
<td>18</td>
<td>16</td>
<td>119</td>
</tr>
<tr>
<td>Biglycan</td>
<td>21</td>
<td>19</td>
<td>18</td>
<td>17</td>
<td>19</td>
<td>18</td>
<td>112</td>
</tr>
</tbody>
</table>

PG, proteoglycan; AB, anterior bursal; AJ, anterior joint; MB, medial bursal; MJ, medial joint; PB, posterior bursal; PJ, posterior joint.
cassettes (0.5–3 mL 20 kDa pore size, #66003, Thermo Fisher Scientific, Rockford, IL, USA). The extract was then extensively dialyzed against ddH2O. The dialysate was removed and centrifuged for 15 min at 15,000 × g at 4°C. A speed-vac (Thermo Savant, Asheville, NC, USA) was utilized to dry the dialyzed extract. Samples were reconstituted at a standardized dry weight/buffer concentration of PBS with the 1× protease inhibitor used above.

PG ELISA
PG content was determined through sandwich ELISA techniques. Decorin content was determined using the Decorin DuoSet ELISA (R&D Systems, Minneapolis, MN, USA) and aggrecan using the PG-EASIA Kit (# KAP1461, Invitrogen, Carlsbad, CA, USA). For these two PGs, the assay was performed as per the manufacturer’s protocol. The recommended dilution of kit-provided standards was used. Dilutions of samples were individually determined by sequential serial dilutions. Of note, aggrecan determination required a wide range of dilutions to reliably read against the standard curves. With respect to aggrecan, the assay was commercialized and designed using antibodies raised against aggrecan molecules purified from cartilage and as such, the precise immune-epitopes are not reported. However, the antibodies (capture and detection) is known to react with the hyaluronan-binding region of the core protein and keratin sulfate-rich regions, respectively. As such, this assay can be used to determine the levels of aggrecan but cannot exclusively relate to its being only aggrecan core protein since it might have some signal coming from aggrecan-associated GAG side chains or remnants thereof. The biglycan and decorin assays utilize recombinant proteins and in these cases, the results are a direct relationship to the concentration of the core protein of each PG.

Biglycan content was determined through a sandwich ELISA technique using a custom-developed assay in our laboratory, as described below. In this assay the L-15 anti-biglycan antibody SC-27936 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was utilized as the capture antibody, anti-human biglycan biotinylated antibody (#BAF2667; R&D Systems) as the detection antibody, and recombinant human biglycan (#2667-CM; R&D Systems) as the standard. In each well of clear polystyrene microplates (R&D system), 0.1 µg of the L-15 anti-biglycan antibody was incubated overnight at room temperature. After aspirating and washing (1× PBS and 0.05% Tween) 3 times (buffer used throughout), the plates were blocked using 300 µL of 1.0% bovine serum albumin in PBS for a minimum of 1 hr. The wells were again washed with buffer 3 times. Samples (100 µL) were allowed to equilibrate with the capture antibody at room temperature for 2 hrs. The plates were then aspirated and washed 3 times. The capture antibody–sample complex was allowed to incubate with the biotinylated detection antibody at a concentration of 250 ng/mL (100 µL) for 2 hrs. The plates were again aspirated and washed 3 times. The capture antibody–sample–detection antibody complex was then conjugated to streptavidin–horseradish peroxidase (DY998; R&D Systems) by incubating the streptavidin–horseradish peroxidase (100 µL) with the complex for 20 min at room temperature. Substrate solution (100 µL/well) (DY999; R&D System) was added to each well and after 20 min of incubation, the optical density was measured at 450 nm using a BioTek Synergy HT Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). The standard curve (range 4 ng/mL to 62.5 pg/mL) was determined by measuring the optical density of the recombinant human biglycan at 450 nm and fitting the data points using a four-parameter logistic curve fit.

Statistics
The overall presence of regional variability for each PG was assessed using Kruskal–Wallis tests with a significance level of p < 0.05. A total of nine comparisons between regions within the bursal portions, between regions within the articular portions, and across bursal and joint portions within a region were made using Mann–Whitney U-tests with a significance level of p < 0.05.

RESULTS
A fundamental obstacle in studying the SST extracellular matrix composition is its inherent resistance to
Figure 2. Concentration of PGs decorin (A), aggrecan (B), biglycan (C) as expressed in µg/mg dry weight in the assayed regions. Only significant comparisons have p-values depicted. PG, proteoglycan; AB, anterior bursal; AJ, anterior joint; MB, medial bursal; MJ, medial joint; PB, posterior bursal; PJ, posterior joint.

disruption and homogenization. In this study, we incorporated the use of a freezer-mill which greatly aided in homogenization and subsequent PG extraction, which is confirmed by measuring GAG in both the extract and residue (by dye-binding GAG assay). To quantify decorin, aggrecan, and biglycan, we expanded on existing methodology for extraction of the components and furthermore we were able to consistently measure core PG content with expected variability with sandwich ELISA techniques. The antibodies used in the assays were PG specific and did not have significant cross-reaction with other PGs. The ELISA assays were very sensitive measures of PG in our samples with sensitivity thresholds of 31, 14,000, and 62 pg/mL for decorin, aggrecan, and biglycan, respectively.

The average concentration (µg/mL) of each PG is normalized by sample dry weight (µg/mg) and shown in Figure 2A–2C and Table 2. For decorin, there were no significant differences between any of the six regions as decorin was present consistently throughout (Figure 2A). For aggrecan, significant differences were observed across regions (Figure 2B, Table 2) with concentrations statistically greater in the anterior and posterior bursal regions when compared to the medial region. There were no differences between aggrecan concentration in the anterior and posterior bursal regions. The concentration of aggrecan in the joint region showed a similar distribution (Figure 2B, Table 2). Biglycan shared a similar, statistically significant distribution between the joint and bursal regions (Figure 2C, Table 2). When the anterior, posterior, and medial regions were compared, aggrecan was present in significantly greater concentrations in the anterior joint region in comparison to the anterior bursal region (Figure 2C, Table 2). Statistical differences between the bursal and joint segments were not observed in either the posterior or medial regions (Figure 2C, Table 2). Biglycan shared a similar distribution, except there was a significantly increased concentration of biglycan in the posterior joint region when compared to the posterior bursal region (Figure 2C, Table 2). No statistical difference was found when comparing the medial bursal and medial joint regions (Figure 2C, Table 2).

DISCUSSION

The objective of this study was to first develop methodology and techniques suitable to assess PG content in the human SST and, second, to determine the PG content in specific regions of the SST that exhibit varying mechanical properties from previous studies. While some qualitative and gene expression information exists
distinct regions of the SST. 

quantitative report of individual PG protein content in the best of our knowledge, this study represents the first on various PGs that make up the tendon [27,28], to we hypothesized that the concentration of decorin regions having the greatest values [21,22]. As a result, the SST primarily experiences tension, our previous mechanical studies indicate clear variations in longitudinal tensile modulus across regions with the medial regions having the greatest values [21,22]. As a result, we expected higher aggrecan expression near the insertion and at the bursal surface under the acromion. Consistent with our hypothesis, we did find increased aggrecan in the anterior (both bursal and joint) and posterior (joint) regions of the SST with decreased amounts elsewhere. This was generally consistent with our previous measurements of tensile mechanics, which showed decreased moduli in regions where the aggrecan concentration was highest.

While biglycan and aggrecan share some expected findings, we hypothesized to find biglycan highest in regions likely subjected to injury and/or active remodeling [23,24]. Consistent with our expectations, we did find increased biglycan levels in the anterior regions (both bursal and joint) and these locations correspond to regions where tears often initiate clinically [11]. Surprisingly, we also found increased biglycan levels in the posterior joint regions. This result was not expected as there are no data in the literature to support that this would mirror these variations in tensile modulus and be highest in the medial regions. Results indicate that decorin appears to be ubiquitous, with no particular regional variation in the SST. This finding was surprising and may indicate that decorin is not particularly sensitive to changes in mechanical properties or collagen fiber organization. This finding is consistent with previous reports suggesting that GAG does not contribute to ligament tensile mechanics [10].

Conversely, aggrecan is the most predominant PG in tissues commonly subjected to compression, such as articular cartilage [24,25]. Located between the humeral head inferiorly and the coracoacromial arch superiorly, in addition to tension, the SST may experience compressive and shear loads, especially near its insertion site. As a result, we expected higher aggrecan expression near the insertion and at the bursal surface under the acromion. Consistent with our hypothesis, we did find increased aggrecan in the anterior (both bursal and joint) and posterior (joint) regions of the SST with decreased amounts elsewhere. This was generally consistent with our previous measurements of tensile mechanics, which showed decreased moduli in regions where the aggrecan concentration was highest.

Table 2. Mean concentration of PGs aggrecan and biglycan as expressed in μg/mg of dry weight

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Concentration (μg/mL)</th>
<th>P-value</th>
<th>Comparison</th>
<th>Concentration (μg/mL)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bursal region</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AB vs. MB</td>
<td>1.4, 0.091</td>
<td>0.0006</td>
<td>AB vs. MB</td>
<td>0.051, 0.014</td>
<td>0.0002</td>
</tr>
<tr>
<td>MB vs. PB</td>
<td>0.091, 0.50</td>
<td>0.0001</td>
<td>MB vs. PB</td>
<td>0.014, 0.028</td>
<td>0.009</td>
</tr>
<tr>
<td>AB vs. PB</td>
<td>1.4, 0.50</td>
<td>0.2</td>
<td>AB vs. PB</td>
<td>0.051, 0.028</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Joint region</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AJ vs. MJ</td>
<td>2.3, 0.084</td>
<td>&lt;0.0001</td>
<td>AJ vs. MJ</td>
<td>0.048, 0.016</td>
<td>0.002</td>
</tr>
<tr>
<td>MJ vs. PJ</td>
<td>0.084, 4.2</td>
<td>&lt;0.0001</td>
<td>MJ vs. PJ</td>
<td>0.016, 0.070</td>
<td>0.0001</td>
</tr>
<tr>
<td>AJ vs. PJ</td>
<td>2.3, 4.2</td>
<td>0.7</td>
<td>AJ vs. PJ</td>
<td>0.048, 0.070</td>
<td>0.8</td>
</tr>
<tr>
<td><strong>Anterior, posterior, medial regions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AB vs. AJ</td>
<td>1.4, 2.3</td>
<td>0.01</td>
<td>AB vs. AJ</td>
<td>0.051, 0.048</td>
<td>0.002</td>
</tr>
<tr>
<td>PB vs. PJ</td>
<td>0.50, 4.2</td>
<td>0.3</td>
<td>PB vs. PJ</td>
<td>0.028, 0.070</td>
<td>0.0001</td>
</tr>
<tr>
<td>MB vs. MJ</td>
<td>0.091, 0.084</td>
<td>0.8</td>
<td>MB vs. MJ</td>
<td>0.014, 0.016</td>
<td>0.8</td>
</tr>
</tbody>
</table>

PG, proteoglycan; AB, anterior bursal; AJ, anterior joint; MB, medial bursal; MJ, medial joint; PB, posterior bursal; PJ, posterior joint. *Mann–Whitney test, two-tailed, with a p-value (p < 0.05). Boldface denotes significance.

There were no significant differences across regions for decorin.

on various PGs that make up the tendon [27,28], to the best of our knowledge, this study represents the first quantitative report of individual PG protein content in distinct regions of the SST.

Regarding methodological development, although extraction of PGs with chaotropic agents such as guanidine after various tissue disruption methods have been well described in the cartilage literature, little information exists describing the effectiveness of extraction in tendon and, in particular, the SST [29,30]. In this study, the use of a freeze mill aided greatly in homogenization, which consistently provided relatively complete extraction of the PG (by measuring total GAGs by a dye-binding assay of the extract and extraction residue, data not shown). In addition, we demonstrated that the sandwich ELISA can be utilized in conjunction with this technique to reliably assess the concentration of various PGs within this clinically important, yet understudied tendon. Notably, our study measured the concentration of aggrecan, decorin, and biglycan proteins, rather than just the GAGs as done previously in tendon [31], and the data are presented on a PG protein—weight basis normalized by dry weight. Therefore, these data do not relate specifically to the combined weight of the core protein plus GAG content. This is important considering that the aggrecan molecule alone is 10 times larger in molecular weight than either decorin or biglycan and potentially has hundreds of attached GAG chains compared to the one or two chains attached to decorin and biglycan, respectively [6].

As decorin is the most predominant tendon PG in general, it is commonly considered the PG most associated with tissues undergoing tension [1–3]. While the SST primarily experiences tension, our previous mechanical studies indicate clear variations in longitudinal tensile modulus across regions with the medial regions having the greatest values [21,22]. As a result, we hypothesized that the concentration of decorin

would mirror these variations in tensile modulus and be highest in the medial regions. Results indicate that decorin appears to be ubiquitous, with no particular regional variation in the SST. This finding was surprising and may indicate that decorin is not particularly sensitive to changes in mechanical properties or collagen fiber organization. This finding is consistent with previous reports suggesting that GAG does not contribute to ligament tensile mechanics [10].

Conversely, aggrecan is the most predominant PG in tissues commonly subjected to compression, such as articular cartilage [24,25]. Located between the humeral head inferiorly and the coracoacromial arch superiorly, in addition to tension, the SST may experience compressive and shear loads, especially near its insertion site. As a result, we expected higher aggrecan expression near the insertion and at the bursal surface under the acromion. Consistent with our hypothesis, we did find increased aggrecan in the anterior (both bursal and joint) and posterior (joint) regions of the SST with decreased amounts elsewhere. This was generally consistent with our previous measurements of tensile mechanics, which showed decreased moduli in regions where the aggrecan concentration was highest.

While biglycan and aggrecan share some expected findings, we hypothesized to find biglycan highest in regions likely subjected to injury and/or active remodeling [23,24]. Consistent with our expectations, we did find increased biglycan levels in the anterior regions (both bursal and joint) and these locations correspond to regions where tears often initiate clinically [11]. Surprisingly, we also found increased biglycan levels in the posterior joint regions. This result was not expected as there are no data in the literature to support that this region is where tears initiate or where active remodeling would be expected. This finding, coupled with high aggrecan levels in this region, is the subject of a future study.
This study is not without limitations. First, although we limited our cadaver shoulder specimens to those without significant shoulder pathology and rotator cuff tears, there is always some inherent variation in size and this resulted in a few specimens being too small to perform the extraction and analysis. We also did not attempt to measure levels of SST degeneration (other than excluding tears) as some level of degeneration is to be expected of SSTs in the age range studied. Although the locations of the samples for biochemical analysis were controlled and consistent, there was a small amount of variation in these locations between shoulder specimens due to small variations in anatomy. Nevertheless, the relatively little variation within groups and the statistically significant comparisons suggest that these minor differences did not affect our results. However, the conclusions drawn by this study are not hindered by these limitations, as we sought only to describe the interregional variability of each PG and not to make a direct comparison between various PGs. Furthermore, the variation in GAG content between like protein cores precludes inter-PG comparison. Thus, the total weight contribution of PG core plus GAG chains cannot be quantitatively expressed. Other methods including mass spectrometry and specialized biochemical assays may aid in this determination. Concomitantly, as the assay of individual PG content in tendons has not been described elsewhere, there exists no confirmatory information of the quantity of each PG core. Our data is supported by qualitative data on the type of PG that comprise a tendon [27,28].

In summary, the data presented in this study represent the first regional measurements of PG protein core in the SST. Given our previous regional measurements of mechanical properties [21,22], these data can be used to evaluate structure–function relationships and may aid in understanding the roles of these PGs in tendon mechanics. With knowledge of the differences in specific PG content, their spatial variations in the SST, and their relationships to tendon mechanics, we can begin to associate defects in PG content with specific pathology, which may provide a platform for new therapeutic interventions.

CONCLUSIONS

Because of the variety of loads encountered by the SST in vivo, the present work aimed to identify regional variations of PGs believed to be correlated with local tissue mechanics, specifically decorin, biglycan, and aggrecan. While decorin concentrations did not vary across tendon locations, aggrecan and biglycan levels were greater in the anterior and posterior regions near the tendon–bone insertion believed to be sites of compressive loading and injury initiation. This is in agreement with findings suggesting structure–function relationships between aggrecan and compressive stiffness as well as findings linking biglycan to wound healing.

Declaration of interest: The authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper. This study was funded by NIH/NIAMS AR055598 which did not influence the results of the project.

REFERENCES


